Mary K. Olson

Tulane University

Professor

Department of Economics

306 Tilton Hall

New Orleans, LA 70118

United States

SCHOLARLY PAPERS

12

DOWNLOADS

17

0

!

Under construction: SSRN citations while be offline until July when we will launch a brand new and improved citations service, check here for more details.

For more information

Scholarly Papers (12)

1.

Does Health IT Save Money and Lives? New Evidence from Vendor Heterogeneity

Number of pages: 55 Posted: 18 Mar 2019
Jianjing Lin and Mary K. Olson
Rensselaer Polytechnic Institute (RPI) - Department of Economics and Tulane University
Downloads 17 (529,168)

Abstract:

Loading...

Health IT, health care expenditure, health care outcome, Medicare

2.

Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity

American Journal of Health Economics, vol. 4, issue 3, Summer 2018, pp. 321-357
Posted: 29 Aug 2018
Mary K. Olson and Nina Yin
Tulane University and Central University of Finance and Economics (CUFE) - China Center for Human Capital and Labor Market Research

Abstract:

Loading...

Innovation Policy, Market Incentives, Pharmaceuticals, Pediatric Exclusivity, FDA Regulation

3.

Firm Characteristics and the Speed of FDA Approval

Journal of Economics and Management Strategy, Vol. 6, No. 2, Summer 1997: 377-401
Posted: 26 Jul 2014
Mary K. Olson
Tulane University

Abstract:

Loading...

FDA regulation, new drug approval, drug review speed

4.

Eliminating the U.S. Drug Lag: Implications for Drug Safety

Journal of Risk and Uncertainty, Vol. 47, Issue 1, pp. 1-30, August 2013
Posted: 10 Aug 2013
Mary K. Olson
Tulane University

Abstract:

Loading...

drug safety, drug approval, drug lag

5.

The Risk We Bear: The Effects of Review Speed and Industry User Fees on New Drug Safety

Journal of Health Economics, Vol. 27, No. 2, 2008
Posted: 21 Mar 2008
Mary K. Olson
Tulane University

Abstract:

Loading...

new-drug review, drug safety, pharmaceutical regulation, FDA, PDUFA

6.

Are Novel Drugs More Risky for Patients than Less Novel Drugs?

Journal of Health Economics, Vol. 23, pp. 1135-1158, November 2004
Posted: 22 Nov 2004
Mary K. Olson
Tulane University

Abstract:

Loading...

New-drug approvals, drug novelty, drug safety, pharmaceutical regulation, FDA

7.

Managing Delegation in the Fda: Reducing Delay in New-Drug Review

Journal of Health Politics, Policy and Law, Forthcoming
Posted: 14 Dec 2003
Mary K. Olson
Tulane University

Abstract:

Loading...

8.

Pharmaceutical Policy Change and the Safety of New Drugs

Journal of Law and Economics, Vol. 45, No. 2, Part 2, October 2002
Posted: 21 Jul 2003
Mary K. Olson
Tulane University

Abstract:

Loading...

pharmaceutical policy, FDA regulation, new-drug safety

9.

Regulatory Reform and Bureaucratic Responsiveness to Firms: The Impact of User Fees in the Fda

Journal of Economics and Management Strategy, Vol. 9, No. 3, Fall 2000
Posted: 18 Oct 2000
Mary K. Olson
Tulane University

Abstract:

Loading...

10.

Agency Rulemaking, Political Influences, Regulation, and Industry Compliance

Journal of Law, Economics, and Organization, Vol. 15, No. 3, Fall 1999
Posted: 21 Sep 1999
Mary K. Olson
Tulane University

Abstract:

Loading...

11.

Regulatory Agency Discretion Among Competing Industries: Inside the Fda

JOURNAL OF LAW, ECONOMICS, AND ORGANIZATION, Vol 11 No 2, Fall 1995)
Posted: 25 Aug 1998
Mary K. Olson
Tulane University

Abstract:

Loading...

12.

Substitution in Regulatory Agencies: Fda Enforcement Alternatives

Journal of Law, Economics, and Organization, Vol. 12, No. 2, Fall 1996.
Posted: 18 Aug 1996
Mary K. Olson
Tulane University

Abstract:

Loading...